Author

F. Bosch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Approach:experimental assay· 4 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:host-pathogen & immune response· 1 Assay:metabolomics· 1

Frequent Co-Authors

A. M. Sponaas· 1 shared A. Martens· 1 shared A. P. Coll· 1 shared A. Sundan· 1 shared B. Ryback· 1 shared B. Stordal· 1 shared B. Y. H. Lam· 1 shared C. Dias· 1 shared

Activity by Year

2017-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. M. Sponaas

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Elevated arginine levels in liver tumors promote metabolic reprogramming and tumor growth

D. Mossmann, S. Park, B. Ryback, D. Weissenberger, M. Colombi, S. K. Hindupur, E. Dazert, M. Coto-Llerena, E. Caner, V. J. Cenzano, S. Piscuoglio, F. Bosch, L. M. Terracciano, U. Sauer, M. N. Hall

The paper shows elevated arginine levels in liver tumors drive metabolic reprogramming and tumor growth through feedback loops involving ASNS and arginase 1.

bioRxiv · Apr 26, 2022 · PreprintCancer Biology

GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activity

M. Ribeiro, N. Profitos-Peleja, J. C. Santos, P. Blecua, D. Reyes Garau, M. Armengol, M. Fernandez-Serrano, H. P. Miskin, F. Bosch, M. Esteller, E. Normant, G. Roue

This study shows that TG-1801 enhances ublituximab's anti-lymphoma activity through GPR183-mediated mechanisms in B-NHL models.

bioRxiv · Mar 31, 2022 · PreprintCancer Biology

Bone morphogenetic protein 4 gene therapy in mice inhibits myeloma tumor growth, but has a negative impact on bone

M. Westhrin, T. Holien, M. Zahoor, S. H. Moen, G. Buene, B. Stordal, H. Hella, H. Yuan, J. D. de Bruijn, A. Martens, R. W. Groen, F. Bosch, U. Smith, A. M. Sponaas, A. Sundan, T. Standal

This study shows that BMP4 gene therapy reduces myeloma tumor growth in mice but also decreases trabecular bone volume.

bioRxiv · Mar 13, 2019Cancer Biology

Loss And Gain Of Function Experiments Implicate TMEM18 As A Mediator Of The Strong Association Between Genetic Variants At Human Chromosome 2p25.3 And Obesity

R. Larder, M. F. M. Sim, P. Gulati, R. Antrobus, Y. C. L. Tung, D. Rimmington, E. Ayuso, J. Polex-Wolf, B. Y. H. Lam, C. Dias, D. W. Logan, S. Virtue, F. Bosch, G. S. H. Yeo, V. Saudek, , A. P. Coll

The paper identifies TMEM18 as a mediator of genetic variants at 2p25.3 associated with obesity through loss and gain of function experiments in mice.

bioRxiv · Mar 31, 2017Physiology